Canakinumab effective for treatment of autoinflammatory diseases:
A recent study that was published in the New England Journal of Medicine showed efficacy in the preventions of inflammatory attacks in patients with colchicine resistent FMF, Hyper IgD syndrome/ Mevalonate Kinase Deficiency and TRAPS. In all three diseases Canakinumab was superior to placebo in controlling inflammation and preventing attacks. In this international multicentre trial there was a significant Belgian contribution.
Reimbursement for Canakinumab in crFMF
The BNAID is happy to announce that after years of lobbying for our patients with autoinflammatory diseases there finally reimbursement of anti-IL1 therapy. In patients with crFMF, TRAPS, HIDS/MKD and sJIA Canakinumab is reimbursed. In addition there is now also reimbursement of Anakinra for CAPS patients.
Second joint symposium of IWA-BNAID 22-23 Novemeber 2018
After a first succesful symposium with our Dutch collegues of the IWA, a second meeting is planned for the 22 and 23st of November 2018. More information about the program and registration is available through this link.